对拉帕提尼布不良反应的全面探索:基于FAERS数据库的不成比例分析
Yao Zhou1,2, Jie Gong1,2, Xianguang Deng1,2
1Department of Galactophore, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
Expert opinion on drug safety
|February 22, 2025
概括
这项研究分析了来自FAERS数据的lapatinib不良事件. 胃肠道和皮肤的毒性很常见,需要对安全的HER2+乳腺癌治疗进行监测.
科学领域:
- 药物监督 药物监督 药物监督
- 在瘤学瘤学.
- 药品安全 药品安全
背景情况:
- 拉帕提尼布是一种FDA批准的铁氨酸激酶抑制剂,用于治疗HER2+高级/转移性乳腺癌.
- 了解其不良反应概况对于临床指导至关重要.
研究的目的:
- 综合分析拉帕提尼布的不良事件 (AE) 概况.
- 通过强大的统计方法识别潜在的安全信号.
主要方法:
- 分析了2007年第二季度至2024年第二季度期间FDA不良事件报告系统 (FAERS) 中的lapatinib AE报告.
- 使用统计方法,包括报告几率比率 (ROR),比例报告比率 (PRR),MGPS和BCPNN来检测AE信号.
主要成果:
- 分析了8300份AE报告,主要来自40-59.9岁 (33.71%) 的女性 (91.47%).
- 胃肠道疾病 (ROR=3.46) 和皮肤疾病 (ROR=2.47) 是最显著的.
- 常见的副作用包括腹,吐和皮疹;更罕见的事件,如中性质衰竭和心周溢出也被注意到. 大多数AEs (51%) 发生在30天内.
结论:
- 拉帕提尼布显示出一个普遍有利的安全性概况.
- 密切监测胃肠道和皮肤毒性对于减轻严重不良事件至关重要.
相关概念视频
01:19Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
01:24Drug Toxicity: Risk factors
248
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
248